Tevogen Bio Holdings Inc. (TVGN)

Compare

1.0900

+0.0100

+(0.93%)

At close: April 1 at 4:00:01 PM EDT

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi’s leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond. This

GlobeNewswire 6 days ago

TVGN
+0.93%
TVGNW
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spe

GlobeNewswire 7 days ago

TVGN
+0.93%
TVGNW
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio.Powered by Tevogen Bio’s artificial intelligence initiative, Tevogen.AI.The company hopes to address public concerns about inoculation during vaccine developm

GlobeNewswire 22 days ago

TVGN
+0.93%
TVGNW
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

Tevogen Bio CIO Speaking at Proskauer's Discussion Panel on AI Tevogen Bio CIO Speaking at Proskauer's Discussion Panel on AI WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, recently joined industry leaders at Proskauer’s AI discussion panel, "Attuned AI: Shaping AI to Empower Your Industry," held on Marc

GlobeNewswire 25 days ago

TVGN
+0.93%
TVGNW
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress, particularly in Tevogen.AI.Efficient operations with operating expenses of $9.7 million for the first three quarters of 2024.The company's AI division has advanced its PredicTcell platform using expanded datasets and wet lab science to enhance predictive modeling capabilities. WARREN, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen

GlobeNewswire 29 days ago

TVGN
+0.93%
TVGNW

MSFT
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies.The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood Advances.A key step in making therapies more accessible was the launch of Tevogen.AI and a partnership with Microsoft. WARREN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech

GlobeNewswire last month

TVGN
+0.93%
TVGNW
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

600% higher market cap per team member when compared to industry average. Source: Mr. Damodaran at the Stern School of Business at NYU.Current ownership breakdown: Insiders 79%; Independent Board Members 1%; Lead Investor 7%; SPAC Sponsor 6%; Others 8%.Assets believed to be valued in the billions. (Not reflected on Tevogen’s balance sheet as internally developed intangible assets are generally not permitted to be capitalized as per US GAAP).Additional business updates to follow in coming days. W

GlobeNewswire last month

TVGN
+0.93%
TVGNW
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company’s 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio’s use. This arrangement, w

GlobeNewswire last month

TVGN
+0.93%
TVGNW
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today issued a statement from its Founder and CEO, Nobel Peace Prize nominee Dr. Ryan Saadi, regarding broader implications of short-selling. “Tevogen Bio is committed to advancing innovative medical solutions while maintaining affordability for patients, a mission that is essential for sustainable healthcare innovation.

GlobeNewswire last month

TVGN
+0.93%
TVGNW

MSFT
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, congratulates Robert F. Kennedy Jr.’s as he begins his role at the head of Health and Human Services. Secretary Kennedy and the administration’s collective goal of achieving accessibility to affordable healthcare in the U.S. aligns with Tevogen Bio’s business model, which focuses on

GlobeNewswire last month

TVGN
+0.93%
TVGNW
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare. With the concern of Chinese pharmaceutical companies developing

GlobeNewswire last month

TVGN
+0.93%
TVGNW
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure

An overview of the ExacTcell technology Mechanism of Action and Development. WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio’s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinica

GlobeNewswire last month

TVGN
+0.93%
TVGNW
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

The grant funding will further Tevogen Bio’s mission to develop therapies for treatment of cancers and viral infections.Tevogen Bio may also utilize the grant funding to further expand its artificial intelligence effort.This grant is in addition to the previously announced $36 million loan agreement from 2Q24. WARREN, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, announced it may re

GlobeNewswire 2 months ago

TVGN
+0.93%
TVGNW

MSFT
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, congratulates Lynne Patton on being appointed Deputy Assistant to the President and Director of Minority Outreach. Ms. Patton will join the Office of Public Liaison and will be responsible for ensuring that President Trump continues to build upon his Election Day support from Blacks, L

GlobeNewswire 2 months ago

TVGN
+0.93%
TVGNW
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

This expansion is in addition to the previously announced Microsoft for Startups program.PredicTcell, Tevogen Bio’s proprietary technology, is designed for predictive, precision T cell target identification. Tevogen Bio is also proactively investigating potential treatments for Human Papillomavirus (HPV). WARREN, N.J., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,

GlobeNewswire 2 months ago

MSFT

TVGN
+0.93%
TVGNW
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, today announced key insights from its recent fireside chat during the J.P. Morgan Healthcare Conference. Utilizing artificial intelligence (AI) and machine learning (ML) has been critical for Tevogen Bio, given its core commit

GlobeNewswire 2 months ago

TVGN
+0.93%
TVGNW

MSFT
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it.AI In Biopharma to highlight how AI-driven technologies can revolutionize d

GlobeNewswire 3 months ago

TVGN
+0.93%
TVGNW
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explor

GlobeNewswire 3 months ago

TVGN
+0.93%
TVGNW

MSFT
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio. In October 2023, Tevogen Bio lau

GlobeNewswire 3 months ago

MSFT

TVGN
+0.93%
TVGNW
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that it will host a compelling panel discussion, “Pioneering the Economics of Health: Balancing Access and Outcomes,” during the 43rd Annual J.P. Morgan Healthcare Conference. This panel will bring together

GlobeNewswire 3 months ago

TVGN
+0.93%
TVGNW

Performance Overview

Return	TVGN	S&P 500 (^GSPC)
YTD	+5.83%	-4.23%
1-Year	-66.21%	+7.42%
3-Year	-89.08%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tevogen Bio Holdings Inc. (TVGN)

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Performance Overview